Sabuwar Magani ga Manya masu fama da Arthritis Psoriatic Active

A KYAUTA Kyauta 5 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

AbbVie, wani kamfanin bincike na duniya na biopharmaceutical, ya sanar da Lafiya Kanada ta amince da SKYRIZI® (risankizumab), don kula da tsofaffi marasa lafiya tare da ciwon huhu na psoriatic. A cikin PsA, SKYRIZI za a iya amfani da ita kadai ko a hade tare da maganin antirheumatic da ba na halitta ba (cDMARD) (misali, methotrexate).   

"SKYRIZI yana karɓar Sanarwa na Yarda da Jiyya na cututtukan cututtukan psoriatic mai aiki yana ba da ƙarin bege ga marasa lafiya. Sakamako daga shirin gwaji na asibiti na Phase 3 yana nuna ci gaba a cikin alamun da alamun da ke hade da wannan cuta, "in ji Dokta Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.

"A AbbVie, muna ƙoƙari don canza ma'auni na kulawa ga mutanen da ba su da rigakafi, kuma muna farin ciki da amincewar Lafiyar Kanada na SKYRIZI don kula da manya da cututtukan cututtuka na psoriatic," in ji Tracey Ramsay, Mataimakin Shugaban kasa da Babban Manajan, AbbVie Canada.  

Wannan shine nuni na biyu ga SKYRIZI a Kanada. A cikin Afrilu 2019, Kiwon Lafiyar Kanada ta amince da SKYRIZI don kula da tsofaffi marasa lafiya tare da matsakaici zuwa matsananciyar plaque psoriasis waɗanda ke takarar neman tsarin jiyya ko phototherapy.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...